-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $90

Benzinga·09/01/2026 17:19:00
Listen to the news
Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $88 to $90.